Consistent with the superior efficacy of HU308 (2.5 mg/kg) over CBD (60 mg/kg) in acute colitis, we extended our investigation to assess the long-term efficacy of HU308 using a chronic model of colitis. This evidence concerns the gene OPN1MW and colitis.